%PDF-1.4
%
52 0 obj
<>
endobj
49 0 obj
<>
endobj
101 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-03-01T12:44:43Z
2024-03-28T16:03:24-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T16:03:24-07:00
application/pdf
Heather
2004-485.april
uuid:ede2afb8-1dd1-11b2-0a00-d509271d5700
uuid:ede2afbb-1dd1-11b2-0a00-bf0000000000
endstream
endobj
38 0 obj
<>
endobj
39 0 obj
<>
endobj
53 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
111 0 obj
[115 0 R]
endobj
112 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(756)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:4)Tj
ET
0 0 0 0 k
/GS0 gs
102.631 82.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.631 82.25 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_1 1 Tf
0.10159 Tw 10 0 0 10 53.468 735.6616 Tm
[(both seen in RA. )17.7 (The mechanisms leading to these abnor-)]TJ
0.06281 Tw 0 -1.29 TD
(malities in arterial function have yet to be fully elucidated.)Tj
-0.0029 Tw T*
[(CRP)110.7 (, which impairs endothelial NO production)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 242.7283 713.1617 Tm
(16)Tj
-0.00011 Tc -0.00301 Tw 10 0 0 10 252.699 709.8616 Tm
(and accel-)Tj
0.172 Tw -19.9231 -1.29 Td
(erates atherosclerosis in a transgenic mouse model)Tj
0 Tc 0 Tw 7.5 0 0 7.5 265.9199 700.2617 Tm
(17)Tj
-0.00011 Tc 0.1721 Tw 10 0 0 10 273.4199 696.9616 Tm
(, has)Tj
0.1608 Tw -21.9952 -1.29 Td
(been suggested as a candidate. In addition, insulin resist-)Tj
0.18829 Tw T*
[(ance, dyslipidemia, and oxidative stress seen in RA)-383.5 (may)]TJ
0 Tw T*
(contribute)Tj
0 Tc 7.5 0 0 7.5 94.0075 661.5616 Tm
(5)Tj
-0.00011 Tc 0.04269 Tw 10 0 0 10 97.7575 658.2617 Tm
(. Recent work suggests that the functional status)Tj
0.0571 Tw -4.4289 -1.29 Td
(of the vasculature, reflected by noninvasive assessments of)Tj
0.0013 Tw T*
(endothelial function, and the structural status of the arteries,)Tj
0.0531 Tw T*
(reflected by atherosclerotic plaque burden, are independent)Tj
0.08459 Tw T*
(predictors of outcome in patients with coronary artery dis-)Tj
-0.0002 Tc 0 Tw T*
(ease)Tj
0 Tc 7.5 0 0 7.5 70.6726 597.0617 Tm
(18)Tj
-0.00011 Tc 0.0108 Tw 10 0 0 10 78.1726 593.7617 Tm
[(. )17.7 (These processes may indicate involvement of dif)17.7 (fer-)]TJ
0.09891 Tw -2.4705 -1.29 Td
[(ent vascular beds and be the result of dif)17.7 (ferent pathogenic)]TJ
0.1501 Tw T*
(mechanisms, but may be equally important or additive in)Tj
0.02499 Tw T*
(terms of eventual cardiovascular outcome.)Tj
0.17 Tw 1.2 -1.17 Td
[(In hypertrophic cardiomyopathy)64.8 (, myocardial microvas-)]TJ
0.2242 Tw -1.2 -1.17 Td
(cular disease predicts a worse cardiovascular outcome)Tj
0 Tc 0 Tw 7.5 0 0 7.5 283.468 534.9617 Tm
(13)Tj
10 0 0 10 290.968 531.6617 Tm
(.)Tj
-0.00011 Tc 0.0313 Tw -23.75 -1.17 Td
[(The mechanisms for this microvascular disease are unclear)39.7 (,)]TJ
0.03391 Tw 0 -1.17 TD
[(but may also relate to endothelial dysfunction. )17.7 (The case we)]TJ
0.0211 Tw T*
[(describe demonstrates that active systemic RA)-216.3 (is associated)]TJ
0.1862 Tw T*
[(with dif)17.7 (fusely impaired myocardial perfusion. It is likely)]TJ
0.1364 Tw T*
(that this is consequent upon microvascular disease, in the)Tj
0.10069 Tw T*
(absence of any significant coronary atheroma on followup)Tj
-0.0325 Tw T*
[(angiography)64.8 (. Importantly)64.8 (, this was reversed following inten-)]TJ
0.2231 Tw T*
(sive immunosuppression and the introduction of simvas-)Tj
0.27029 Tw T*
[(tatin. )17.7 (This is analogous to the improvement in brachial)]TJ
0.196 Tw T*
(artery endothelial function seen following treatment with)Tj
0.03841 Tw T*
(steroid and cyclophosphamide in primary systemic vasculi-)Tj
-0.0002 Tc 0 Tw T*
(tis)Tj
0 Tc 7.5 0 0 7.5 62.9138 394.5618 Tm
(8)Tj
-0.00011 Tc 0.11211 Tw 10 0 0 10 70.2853 391.2618 Tm
[(and with anti-tumor necrosis factor)19.7 (-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.1122 Tw 15.8039 0 Td
(therapy in RA)Tj
0 Tc 0 Tw 7.5 0 0 7.5 287.218 394.5618 Tm
(6)Tj
10 0 0 10 290.968 391.2618 Tm
(.)Tj
-0.00011 Tc 0.11481 Tw -23.75 -1.17 Td
[(As in hypertrophic cardiomyopathy)64.8 (, myocardial microvas-)]TJ
-0.0123 Tw T*
(cular disease may be associated with a worse cardiovascular)Tj
0.04961 Tw T*
[(outcome in RA. )17.7 (The timing of the angiography in this case)]TJ
0.0347 Tw T*
(means that we cannot exclude the possibility that the initial)Tj
0.3307 Tw T*
(perfusion defects were due to coronary atherosclerosis,)Tj
0.0847 Tw T*
(which regressed with immunosuppression and statin thera-)Tj
0.114 Tw T*
[(py)64.8 (. )54.8 (Although an exciting possibility)64.8 (, such remodeling of a)]TJ
0.0507 Tw T*
(fixed lesion is less likely than an improvement in the func-)Tj
0.1216 Tw T*
[(tional status of the microvasculature following therapy)64.8 (. In)]TJ
0.1124 Tw T*
(addition, the separate contributions of immunosuppression)Tj
0.0912 Tw T*
[(\(with steroid, MTX, and cyclosporin )54.8 (A\) and statin therapy)]TJ
-0.0148 Tw T*
(\(which itself has immunomodulatory and cholesterol-lower-)Tj
-0.011 Tw T*
[(ing ef)17.7 (fects)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 95.0961 242.4618 Tm
(19,20)Tj
-0.00011 Tc -0.011 Tw 10 0 0 10 111.9711 239.1618 Tm
(\) to the improvement in myocardial perfusion)Tj
-0.0177 Tw -5.8503 -1.17 Td
[(cannot be defined in an individual case such as this. )17.8 (There is)]TJ
0.2919 Tw T*
[(clearly a need for a prospective study of the ef)17.7 (fect of)]TJ
0.18201 Tw T*
(rheumatoid disease activity on myocardial perfusion, and)Tj
0.0209 Tw T*
(the ability of traditional immunosuppression or statin thera-)Tj
0.02499 Tw T*
(py to reverse any defect.)Tj
-0.0152 Tw 1.2 -1.2 Td
(This case challenges the current assumption that myocar-)Tj
0.03979 Tw -1.2 -1.2 Td
[(dial ischemia and its adverse sequelae in RA)-235 (are due solely)]TJ
0.07961 Tw 0 -1.2 TD
[(to accelerated atherosclerosis af)17.7 (fecting the epicardial coro-)]TJ
0.04131 Tw T*
(nary arteries, and suggests that the myocardial microvascu-)Tj
0.22189 Tw T*
[(lature may also be important. )17.7 (The observation that such)]TJ
0.2076 Tw T*
(microvascular abnormalities are reversible with immuno-)Tj
0.10339 Tw T*
(suppression may have therapeutic implications for chronic)Tj
-0.0033 Tw 26.4 63.9 Td
(inflammatory rheumatic disorders associated with increased)Tj
0.02499 Tw T*
[(cardiovascular mortality)64.8 (.)]TJ
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 324.468 689.6616 Tm
[(1.)-875.1 (V)110.8 (an Doornum S, McColl G, )17.7 (W)39.8 (icks IP)110.7 (. )54.8 (Accelerated atherosclerosis:)]TJ
1.675 -1.25 Td
[(an extraarticular feature of rheumatoid arthritis? )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw 0 -1.25 TD
(2002;46:862-73.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Kitas G, Banks MJ, Bacon P)91.7 (A. Cardiac involvement in rheumatoid)]TJ
1.675 -1.25 Td
(disease. Clin Med 2001;1:18-21.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Park )36.8 (YB, )54.8 (Ahn CW)91.7 (, Choi HK, et al. )54.8 (Atherosclerosis in rheumatoid)]TJ
1.675 -1.25 Td
(arthritis: morphologic evidence obtained by carotid ultrasound.)Tj
T*
(Arthritis Rheum 2002;46:1714-9.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Banks M, Flint J, Bacon P)91.7 (A, Kitas GD. Rheumatoid arthritis is an)]TJ
1.675 -1.25 Td
(independent risk factor for ischaemic heart disease [abstract].)Tj
T*
(Arthritis Rheum 2000;43 Suppl: S385.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Sattar N, McCarey DW)91.7 (, Capell H, McInnes IB. Explaining how)]TJ
1.675 -1.25 Td
(\322high-grade\323 systemic inflammation accelerates vascular risk in)Tj
T*
(rheumatoid arthritis. Circulation 2003;108:2957-63.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Hurlimann D, Forster )54.8 (A, Noll G, et al. )54.8 (Anti-tumor necrosis factor)19.7 (-)]TJ
1.675 -1.25 Td
(alpha treatment improves endothelial function in patients with)Tj
T*
(rheumatoid arthritis. Circulation 2002;106:2184-7.)Tj
-1.675 -1.2 Td
[(7.)-875.1 (Klocke R, Cockcroft JR, )17.7 (T)69.9 (aylor GJ, Hall IR, Blake DR. )54.8 (Arterial)]TJ
1.675 -1.2 Td
[(stif)17.7 (fness and central blood pressure, as determined by pulse wave)]TJ
0 -1.2 TD
[(analysis, in rheumatoid arthritis. )54.8 (Ann Rheum Dis 2003;62:414-8.)]TJ
-1.675 -1.2 Td
[(8.)-875.1 (Raza K, )17.7 (Thambyrajah J, )17.7 (T)69.9 (ownend JN, et al. Suppression of)]TJ
1.675 -1.2 Td
(inflammation in primary systemic vasculitis restores vascular)Tj
T*
(endothelial function: lessons for atherosclerotic disease?)Tj
T*
(Circulation 2000;102:1470-2.)Tj
-1.675 -1.2 Td
[(9.)-875.1 (Filer )54.8 (AD, Gardner)19.7 (-Medwin JM, )17.7 (Thambyrajah J, et al. Dif)17.7 (fuse)]TJ
1.675 -1.2 Td
[(endothelial dysfunction is common to )54.8 (ANCA)-220.2 (associated systemic)]TJ
T*
[(vasculitis and polyarteritis nodosa. )54.8 (Ann Rheum Dis 2003;62:162-7.)]TJ
-2.175 -1.2 Td
[(10.)-875.1 (Booth )54.8 (AD, )17.7 (W)79.9 (allace S, McEniery CM, et al. Inflammation and)]TJ
2.175 -1.2 Td
[(arterial stif)17.7 (fness in systemic vasculitis: )54.7 (A)-220.1 (model of vascular)]TJ
T*
[(inflammation. )54.8 (Arthritis Rheum 2004;50:581-8.)]TJ
-2.1381 -1.2 Td
[(1)36.8 (1)-0.1 (.)-875.1 (W)79.9 (estedt ML, Meijer CJ, )17.7 (V)110.8 (ermeer BJ, Cats )54.8 (A, de )17.7 (V)59.8 (ries E.)]TJ
2.1381 -1.2 Td
(Rheumatoid arthritis \321 the clinical significance of histo- and)Tj
T*
(immunopathological abnormalities in normal skin. J Rheumatol)Tj
0 Tc 0 Tw T*
[(1984;1)36.9 (1:448-53.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.2 Td
[(12.)-875.1 (Bacon P)91.7 (A, Raza K, Banks MJ, )17.7 (T)69.9 (ownend J, Kitas GD. )17.7 (The role of)]TJ
2.175 -1.2 Td
(endothelial cell dysfunction in the cardiovascular mortality of RA.)Tj
T*
(Int Rev Immunol 2002;21:1-17.)Tj
-2.175 -1.2 Td
[(13.)-875.1 (Cecchi F)79.7 (, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG.)]TJ
2.175 -1.2 Td
(Coronary microvascular dysfunction and prognosis in hypertrophic)Tj
0 Tc T*
[(cardiomyopathy)64.9 (. N Engl J Med 2003;349:1027-35.)]TJ
-0.00011 Tc -2.175 -1.2 Td
[(14.)-875.1 (Mahmarian JJ, Moye LA, )17.7 (V)110.8 (erani MS, Bloom MF)79.7 (, Pratt CM. High)]TJ
2.175 -1.2 Td
(reproducibility of myocardial perfusion defects in patients)Tj
T*
[(under)17.7 (going serial exercise thallium-201 tomography)64.8 (. )54.8 (Am J Cardiol)]TJ
0 Tc 0 Tw T*
[(1995;75:1)36.9 (1)36.9 (16-9.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.2 Td
[(15.)-875.1 (Kitas GD, Erb N. )17.7 (T)69.9 (ackling ischaemic heart disease in rheumatoid)]TJ
2.175 -1.2 Td
(arthritis. Rheumatology Oxford 2003;42:607-13.)Tj
-2.175 -1.2 Td
[(16.)-875.1 (V)110.8 (erma S, )17.7 (W)79.9 (ang CH, Li SH, et al. )54.8 (A)-220.1 (self-fulfilling prophecy: )]TJ
2.175 -1.2 Td
(C-reactive protein attenuates nitric oxide production and inhibits)Tj
T*
(angiogenesis. Circulation 2002;106:913-9.)Tj
-2.175 -1.2 Td
[(17.)-875.1 (Paul )54.8 (A, Ko KW)91.7 (, Li L, et al. C-reactive protein accelerates the)]TJ
2.175 -1.2 Td
(progression of atherosclerosis in apolipoprotein E-deficient mice.)Tj
T*
(Circulation 2004;109:647-55.)Tj
-2.175 -1.2 Td
[(18.)-875.1 (Chan SY)128.8 (, Mancini GB, Kuramoto L, Schulzer M, Frohlich J,)]TJ
2.175 -1.2 Td
[(Ignaszewski )54.8 (A. )17.7 (The prognostic importance of endothelial)]TJ
T*
(dysfunction and carotid atheroma burden in patients with coronary)Tj
T*
[(artery disease. J )54.8 (Am Coll Cardiol 2003;42:1037-43.)]TJ
-2.175 -1.2 Td
[(19.)-875.1 (Leung BP)110.7 (, Sattar N, Crilly )54.8 (A, et al. )54.8 (A)-220.1 (novel anti-inflammatory role)]TJ
2.175 -1.2 Td
(for simvastatin in inflammatory arthritis. J Immunol)Tj
0 Tc 0 Tw T*
(2003;170:1524-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2 Td
[(20.)-875.1 (McCarey DW)91.7 (, McInnes IB, Madhok R, et al. )17.7 (T)35 (rial of )54.8 (Atorvastatin)]TJ
2.175 -1.2 Td
[(in Rheumatoid )54.7 (Arthritis \(T)79.7 (ARA\): double-blind, randomised)]TJ
T*
(placebo-controlled trial. Lancet 2004;363:2015-21.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
32 0 obj
<>stream
8;Z\6!H,h0#g<64aEJu5_3cK)OD?^f\nIRZCCY1$!CXZf+0F*1*o*J!lh*c@
7hnYkCHAPZ.+9M4'MYOo#
[C7WVP1BG!`=#3I33'Y%":VS=6s0-c=#'#h/0MhX3Nc`&Hb^Ya=bdnO4:3REe^j_/
;5@,17;5okdg;\`(D7`s)HSu_1'GQO]eJnOSLmdihM=7rT=;>]]`W:L+#Y*eXL*0*
=A?h$=H3Y,BpMp/NhS"tJ>)h[YngWGDip#Po=tC.Tk!@%E2NdXTj]KHr"$F-RCCKB@u_jBPb$mE5g`PqD3FT+kqnim(^;rq!g!I3-IgE
0ScN)LJFC298,u?k1CnrVk&!D$*mN/Fu[^g/GET_7^Zr>G"^jn@FB4*TXW)%uTW7QF6D(9XB]
endstream
endobj
36 0 obj
[/Indexed/DeviceRGB 255 35 0 R]
endobj
35 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
57 0 obj
<>
endobj
59 0 obj
<>
endobj
23 0 obj
<>
endobj
79 0 obj
<>
endobj
94 0 obj
<>
endobj
106 0 obj
<>
endobj
78 0 obj
<>
endobj
89 0 obj
<>stream
HLS{PTUeUzRL]FybR¢.Y
T`vCED|EqE|YLXc#qHfݵpΙo|s}wh*4i:"iaX̎IvkN0(e4 Qx2,TLS-~\U_'2:vffEPZ-9m4FM6cg%5 bT|\$cQLʱ2a*ZI,L9